We aim for the first FDA-approved oral ketamine for severe depression, safe enough for care at home.
NeoPhore grew from our founders' Nature-published work using DNA repair inhibition to boost cancer immunity.
PhoreMost used Protein Interference screening to unmask hidden druggable sites across the human genome.
I led NeoPhore's push to build small-molecule drugs that spark cancer neoantigens for immunotherapy.
During the pandemic I volunteered at UK Biocentre's Lighthouse labs for about ten months.
I'm CEO of Neurocentrx Pharma, a biotech developing oral ketamine treatments.
We aim for the first FDA-approved oral ketamine for severe depression, safe enough for care at home.
NeoPhore grew from our founders' Nature-published work using DNA repair inhibition to boost cancer immunity.
PhoreMost used Protein Interference screening to unmask hidden druggable sites across the human genome.
I led NeoPhore's push to build small-molecule drugs that spark cancer neoantigens for immunotherapy.
During the pandemic I volunteered at UK Biocentre's Lighthouse labs for about ten months.
I'm CEO of Neurocentrx Pharma, a biotech developing oral ketamine treatments.
We aim for the first FDA-approved oral ketamine for severe depression, safe enough for care at home.
NeoPhore grew from our founders' Nature-published work using DNA repair inhibition to boost cancer immunity.
PhoreMost used Protein Interference screening to unmask hidden druggable sites across the human genome.
I led NeoPhore's push to build small-molecule drugs that spark cancer neoantigens for immunotherapy.
During the pandemic I volunteered at UK Biocentre's Lighthouse labs for about ten months.
By using this service, you agree to the Terms of Service and Privacy Policy.